Diagnostic work-up of carcinoma of unknown primary: From immunohistochemistry to molecular profiling

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Oien, K A ^a   Dennis, J L ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer; Immunohistochemistry; Metastatic; Molecular profiling; Pathology; Unknown primary

Indexed keywords

ASPARTIC PROTEINASE; BIOLOGICAL MARKER; CYTOKERATIN 20; CYTOKERATIN 7; MESSENGER RNA; MICRORNA; NAPSIN A; OCTAMER TRANSCRIPTION FACTOR 4; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG;

ARTICLE; CANCER CLASSIFICATION; CANCER CYTODIAGNOSIS; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION PROFILING; GOLD STANDARD; HUMAN; IMMUNOHISTOCHEMISTRY; INSTRUMENT VALIDATION; INTERMETHOD COMPARISON; MOLECULAR DIAGNOSIS; NKX3.1 GENE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; UNDIFFERENTIATED CARCINOMA;

ADENOCARCINOMA; CARCINOMA; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MICRORNAS; NEOPLASMS, UNKNOWN PRIMARY; TUMOR MARKERS, BIOLOGICAL;

EID: 84866763589     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds357     Document Type: Article

References (49)

1. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet 2012; 379: 1428-1435.
2. Massard C, Loriot Y, Fizazi K. Carcinomas of an unknown primary origin- diagnosis and treatment. Nat Rev Clin Oncol 2011; 8: 701-710.
3. Fizazi K, Greco FA, Pavlidis N et al. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22(Suppl 6): vi64-vi68.
4. National Institute for Health and Clinical Excellence. Metastatic Malignant Disease of Unknown Primary Origin: Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin. London: National Institute for Health and Clinical Excellence 2010; CG104.
5. Greco FA, Oien K, Erlander M et al. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol 2012; 23: 298-304.
6. Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol 2009; 36: 8-37.
7. Bahrami A, Truong LD, Ro JY. Undifferentiated tumor-true identity by immunohistochemistry. Arch Pathol Lab Med 2008; 132: 326-348.
8. Laury AR, Perets R, Piao H et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 2011; 35: 816-826.
9. Turner BM, Cagle PT, Sainz IM et al. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med 2012; 136: 163-171.
10. Ramskold D, Wang ET, Burge CB et al. An abundance of ubiquitously expressed genes revealed by tissue transcriptome sequence data. PLoS Comput Biol 2009; 5: e1000598.
11. Gevaert O, Daemen A, De Moor B et al. A taxonomy of epithelial human cancer and their metastases. BMC Med Genomics 2009; 2: 69.
12. Anderson GG, Weiss LM. Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. Appl Immunohistochem Mol Morphol 2010; 18: 3-8.
13. Monzon FA, Lyons-Weiler M, Buturovic LJ et al. Multicenter Validation of a 1,550-Gene Expression Profile for Identification of Tumor Tissue of Origin. J Clin Oncol 2009; 27: 2503-2508.
14. Centeno BA, Bloom G, Chen DT et al. Hybrid model integrating immunohistochemistry and expression profiling for the classification of carcinomas of unknown primary site. J Mol Diagn 2010; 12: 476-486.
15. Hashimoto K, Sasajima Y, Ando M et al. Immunohistochemical profile for unknown primary adenocarcinoma. PLoS One 2012; 7: e31181.
16. Gurel B, Ali TZ, Montgomery EA et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol 2010; 34: 1097-1105.
17. Pereira TC, Share SM, Magalhaes AV et al. Can we tell the site of origin of metastatic squamous cell carcinoma? An immunohistochemical tissue microarray study of 194 cases. Appl Immunohistochem Mol Morphol 2011; 19: 10-14.
18. Weiss LM, Chu PG, Schroeder BE et al. Blinded comparator study of immunohistochemistry (IC) versus a 92-gene cancer classifier in the diagnosis of primary site in metastatic tumors. J Clin Oncol 2012; 30: e21019.
19. Schroeder BE, Laouri M, Chen E et al. Pathological diagnoses in cases of indeterminate or unknown primary submitted for molecular tumor profiling. Lab Invest 2012; 92: 105A-106A.
20. Erlander MG, Ma X-J, Kesty NC et al. Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn 2011; 13: 493-503.
21. Hainsworth JD, Pillai R, Henner WD et al. Molecular tumor profiling in the diagnosis of patients with carcinoma of unknown primary site: retrospective evaluation of gene microarray assay. J Mol Biomarkers Diagn 2011; 2: 106.
22. Dennis JL, Hvidsten TR, Wit EC et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005; 11: 3766-3772.
23. Pillai R, Deeter R, Rigl CT et al. Validation and reproducibility of a microarraybased gene expression test for tumor identification in formalin-fixed, paraffinembedded specimens. J Mol Diagn 2011; 13: 48-56.
24. Meiri E, Mueller WC, Rosenwald S et al. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist 2012; 17: 801-812.
25. Takei H, Monzon FA. Gene-expression assays and personalized cancer care: tissue-of-origin test for cancer of unknown primary origin. Pers Med 2011; 8: 429-436.
26. Monzon FA, Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med 2010; 134: 216-224.
27. Handorf CR. Gene expression analysis and immunohistochemistry in evaluation of cancer of unknown primary: time for a patient-centered approach. J Natl Compr Cancer Netw 2011; 9: 1415-1420.
28. Bender RA, Erlander MG. Molecular classification of unknown primary cancer. Semin Oncol 2009; 36: 38-43.
29. Monzon FA, Dumur CI. Diagnosis of uncertain primary tumors with the pathwork tissue-of-origin test. Expert Rev Mol Diagn 2010; 10: 17-25.
30. Dumur CI, Fuller CE, Blevins TL et al. Clinical verification of the performance of the pathwork tissue of origin test: utility and limitations. Am J Clin Pathol 2011; 136: 924-933.
31. Stancel GA, Coffey D, Alvarez K et al. Identification of tissue of origin in body fluid specimens using a gene expression microarray assay. Cancer Cytopathol 2012; 120: 62-70.
32. Grenert JP, Smith A, Ruan W et al. Gene expression profiling from formalin-fixed, paraffin-embedded tissue for tumor diagnosis. Clin Chim Acta 2011; 412: 1462-1464.
33. Kerr SE, Schnabel CA, Sullivan PS et al. Multisite Validation Study To Determine Performance Characteristics of a 92-gene Molecular Cancer Classifier. Clin Cancer Res 2012; 18: 3592-3960.
34. Kerr SE, Schnabel CA, Sullivan PS et al. Use of a 92-gene molecular classifier to predict the site of origin for primary and metastatic tumors with neuroendocrine differentiation. Lab Invest 2012; 92: 147A.
35. Greco FA, Spigel DR, Yardley DA et al. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 2010; 15: 500-506.
36. Sanden M, Pentheroudakis G, St Cyr B et al. A novel microRNA-based test demonstrate above 90% accuracy in classification of metastatic tumors from patients diagnosed with carcinoma of unknown primary. Lab Invest 2012; 92: 456A.
37. Beck AH, Rodriguez-Paris J, Zehnder J et al. Evaluation of a gene expression microarray-based assay to determine tissue type of origin on a diverse set of 49 malignancies. Am J Surg Pathol 2011; 35: 1030-1037.
38. Ma XJ, Patel R, Wang XQ et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006; 130: 465-473.
39. Nystrom SJ, Hornberger JC, Varadhachary GR et al. Clinical utility of geneexpression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival. Oncotarget 2012; 3: 620-628.
40. Laouri M, Halks-Miller M, Henner WD et al. Potential clinical utility of geneexpression profiling in identifying tumors of uncertain origin. Pers Med 2011; 8: 615-622.
41. Hainsworth JD, Schnabel CA, Erlander MG et al. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer 2012; 11: 112-118.
42. Greco FA, Rubin MS, Boccia RV et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients (pts) with carcinoma of unknown primary site (CUP): results of a prospective Sarah Cannon Research Institute (SCRI) trial. J Clin Oncol 2012; 42: e10530.
43. Tothill RW, Kowalczyk A, Rischin D et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005; 65: 4031-4040.
44. Ferracin M, Pedriali M, Veronese A et al. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol 2011; 225: 43-53.
45. Fernandez AF, Assenov Y, Martin-Subero JI et al. A DNA methylation fingerprint of 1628 human samples. Genome Res 2012; 22: 407-419.
46. Talantov D, Baden J, Jatkoe T et al. A quantitative reverse transcriptasepolymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn 2006; 8: 320-329.
47. Varadhachary GR, Talantov D, Raber MN et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008; 26: 4442-4448.
48. Ojala KA, Kilpinen SK, Kallioniemi OP. Classification of unknown primary tumors with a data-driven method based on a large microarray reference database. Genome Med 2011; 3: 63.
49. Quon G, Morris Q. ISOLATE: a computational strategy for identifying the primary origin of cancers using high-throughput sequencing. Bioinformatics 2009; 25: 2882-2889.